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Advances in sequencing technology have taught us
much about the human genome, including how
difficult it is to interpret rare variation. Improvements
in genetic test interpretation are likely to come
through data sharing, international collaborative
efforts to develop disease–gene specific guidelines,
and computational analyses using big data.ome is not easily tamed and as a field we have had toGenetic testing is a rapidly growing part of medicine. In-
surer UnitedHealth estimates that the genetic testing
market will increase fivefold in the next 5 years [1]. The
number of clinically available genetic tests for rare Men-
delian disorders has been rising rapidly, and as of this
writing has surpassed 60,000 [1]. In the realm of pre-
ventative medicine, projects like Geisinger’s MyCode
and National Institutes of Health (NIH) ClinSeq aim to
explore the role of sequencing in predicting disease in
healthy individuals. Yet, the benefit patients reap from
genetic testing is entirely dependent on our ability to
interpret the results.Insights from broad sequencing initiatives
Several factors have come together in recent years to
make the clinical genetics community re-evaluate our
approach to the interpretation of molecular genetic tests.
Analysis of the exomes of tens of thousands of individ-
uals in projects like those that make up the Exome Ag-
gregation Consortium (ExAC) have revealed that rare
variation is far more abundant in the human genome
than previously thought [2]. This calls into question
both the field’s prior assumption that most rare variation
causes severe Mendelian genetic disease and the specific* Correspondence: euan@stanford.edu
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heavily on our prior assumptions regarding rarity. At the
same time, data-sharing efforts revealed that laboratories
do not always agree in their interpretation of genetic test
results. An analysis of nearly 13,000 variants in ClinVar
with classifications by more than one laboratory found
that in 17 % of cases the laboratories’ classifications dif-
fered [3].
These data inspire a fair amount of humility. The gen-
face that we are not as good at interpreting it as we had
hoped. Variant interpretation is an inherently challen-
ging endeavor. It is a probabilistic assessment of the like-
lihood that a given variant is disease-causing (Fig. 1). A
myriad of data types inform that assessment and we
rarely have all of the data points we would like to have,
either because they simply do not exist or because they
are not shared publicly.New guidelines
It is within this context that the American College of
Medical Genetics and Genomics (ACMG) and the Asso-
ciation for Molecular Pathology (AMP) published new
recommendations for the interpretation of sequence var-
iants in early 2015 [4]. The new recommendations de-
tailed a scoring system that gave different weights to
different types of evidence and leads to a classification of
pathogenic, likely pathogenic, uncertain significance,
likely benign, or benign. While these categories appear
discrete, they really are points on a spectrum of likeli-
hood of pathogenicity (Fig. 1). Clinically, variants
deemed pathogenic or likely pathogenic are often used
in making diagnoses, assessing risk of disease in healthy
relatives, and reproductive genetic testing. These rec-
ommendations were intended to provide general guid-
ance with the understanding that both gene-specific
knowledge and clinical judgment would be needed for
effective implementation.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Fig. 1 Genetic test interpretation is probabilistic. Variants found
through genetic testing are classified as benign, likely benign,
uncertain significance, likely pathogenic, or pathogenic. These
various classifications fall along a spectrum of likelihood that the
variant is disease causing, with benign at one end, pathogenic at
the other, and a broad range of uncertainty in the middle.
Reproduced with permission from [11]
Caleshu and Ashley Genome Medicine  (2016) 8:70 Page 2 of 3Putting the new guidelines into practice
An effort to test the new ACMG–AMP recommenda-
tions in practice was published recently in the American
Journal of Human Genetics [5]. Nine variants were clas-
sified by nine laboratories and a further 90 variants were
randomly assigned to three of the nine laboratories. The
participating laboratories are members of the Clinical
Sequencing Exploratory Research Consortium (CSER),
an NIH-funded multicenter initiative aimed at generat-
ing evidence to guide the application of sequencing to
medical care [6]. Using their own internal classification
methods, the laboratories agreed on the classification of
34 % of the variants. Interestingly, when the laboratories
classified the variants using the new ACMG–AMP cri-
teria their level of agreement did not increase. Through
discussion among the laboratories the level of agreement
was raised from 34 to 71 %. While 29 % of variants did
not reach consensus after discussion, only 5 % differed
in a manner likely to affect medical management
(i.e., likely pathogenic or pathogenic versus any other
classification).
The markedly low level of initial agreement among la-
boratories using either internal methods or the new
ACMG–AMP methods (34 %) is a striking finding. It is
not clear what criteria the laboratories used to select
these variants. Ascertainment bias could have impacted
the observed level of agreement; if the laboratories se-
lected particularly challenging or controversial variants
that would have inflated the rate of disagreement. The
prior report of 17 % disagreement among submitters in
ClinVar may be a better estimate of the overall rate of
disagreement in classification between laboratories [3].
Interestingly, we have found a similar rate of disagree-
ment between our clinical team and genetic testing la-
boratories; in an analysis of 578 variants in our clinical
cohort our classification differed from the testing labora-
tory 20 % of the time (CC, unpublished data).
It is notable and somewhat discouraging that applica-
tion of the new ACMG–AMP recommendations did not
initially increase agreement between laboratories. Inter-
estingly, the authors found that this was partially due to
the nuances of how the ACMG–AMP criteria wereapplied. Some disagreement in classifications occurred
because the laboratories used a given rule differently or
differed in their decisions about whether a specific rule
was met. This suggests that detailed instructions may
be needed to ensure consistent and appropriate use of
classification rules. Differences in gene–disease spe-
cific expertise also played a role in disagreements be-
tween laboratories.
The way forward
While these recent findings may spark some concern re-
garding the interpretability of sequence-based genetic
tests, we believe that there is ample room for hope. Im-
provements in genetic test interpretation are coming
from data sharing, international collaborations to create
gene–disease specific guidelines, and insights into patho-
genic and benign variation gained from big data. Our
understanding of the genome and its variation has im-
proved immensely in recent years and that understand-
ing can be harnessed to improve interpretation of
clinical genetic tests.
Both the ACMG–AMP guidelines and the articles by
Amendola et al. point out the need for gene and, in
some cases, gene–disease specific guidance on elements
like allele frequency thresholds for assessing rarity, clin-
ical validity of functional assays, and the role of loss of
function variants [4, 5]. Through the ClinGen project,
groups comprising international experts on specific dis-
eases are developing just this sort of guidance [3]. For
example, the first initiative tackled by ClinGen’s Cardio-
vascular Domain Working Group has been modification
of the original ACMG–AMP recommendations specific-
ally for classification of MYH7 variants for cardiomyop-
athy. The majority of the needed modifications were
either to remove rules not applicable toMYH7 or to refine
rules to make them more specific to this gene–disease
pair. Initial testing of these MYH7-cardiomyopathy spe-
cific rules shows a high level of concordance [7]. Similar
efforts are underway for other disease–gene pairs [4].
Variant interpretation will continue to benefit from in-
creased data sharing, exemplified by projects such as
ExAC and databases like ClinVar [2]. Efforts are being
made to resolve disagreement among laboratories sub-
mitting to ClinVar; in one such effort 15 % of differences
could be resolved by sharing internal, unpublished data
[8]. While these efforts are both needed and laudable, it
is important that we aim not only to agree with one an-
other in our classifications, but also to ensure that our
classifications are correct and likely to stand the test of
time.
We recently used sequence data on 2913 individuals
with hypertrophic cardiomyopathy from the international
Sarcomeric Human Cardiomyopathy Registry (SHaRe)
and 103,636 individuals not selected for Mendelian
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structure of the myosin heavy chain molecule are intoler-
ant to variation [9]. The findings can help laboratories and
clinicians assess the likelihood of pathogenicity of any
MYH7 variant. At the gene level, Walsh et al. recently
compared the burden of rare variation in 7855 cardiomy-
opathy cases and 60,706 ExAC exomes to assess the
strength of reported associations between select genes and
hereditary cardiomyopathies [10]. Analyses like these are
only possible with large-scale international data sharing.
Clinicians also have to be active and critical con-
sumers, carefully reviewing the rationale for the classifi-
cations they receive from genetic testing companies.
This includes checking ClinVar, reviewing the primary
data, and, if possible, making their own assessments of
the appropriate classification. We have found this has
become common practice among cardiovascular genetics
groups like ours, with 81 % of cardiovascular genetic
counselors reporting that their clinical team assesses the
classification of variants they receive through clinical
genetic testing. Periodic re-assessment of classifications
is critical as medically impactful classification changes
will occur in a subset. Outdated classifications were re-
sponsible for nearly a quarter of discordance in ClinVar
in one study [8].
Conclusion
Genetic test interpretation remains challenging, with a
significant need for improved methods. Effective variant
interpretation guidelines should be gene–disease specific,
data driven, and precise in implementation instructions.
Sharing of case data by clinical laboratories, researchers,
and clinicians alike is critical to optimization of variant
classification. Comparison of rare variation in large co-
horts of Mendelian disease cases and unselected individ-
uals is providing valuable insight into the location and
nature of pathogenic variation, which can in turn inform
genetic test interpretation. Combined with our rapidly
growing understanding of the genome, these efforts offer
hope for improvement in our ability to make meaningful
use of genomic variation in medical care.
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